Prof. Jingfeng Liu 刘景丰
Chief Physician, Professor
Department of Hepatobiliary and Pancreatic Oncology Surgery, Fujian Cancer Hospital, Fuzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of liver diseases, portal hypertension, pancreatic diseases, and liver transplantation.
Dr. Liu holds a PhD and serves as Professor, Doctoral Supervisor, and Chief Physician. The doctor works in general surgery, hepatobiliary surgery, and liver transplantation, establishing technical systems for liver tumor surgery and transplantation for end-stage liver disease. Dr. Liu has extensive experience in the surgical diagnosis and treatment of hepatobiliary diseases.
Professional roles
- Member, Chinese Medical Association
- Standing Committee Member, Hepatology Branch, Chinese Medical Association
- Standing Committee Member, Biliary Tract Tumor Committee, China Anti-Cancer Association
- Co-Chair, China Branch, International Hepato-Pancreato-Biliary Association
Name order: in Chinese the family name comes first (Liu Jingfeng). Papers usually list the name as Jingfeng Liu or Liu J.
Selected publications
71 papers on PubMed matched by name and affiliation; 38 as first or senior author since 2016. Most recent first- or senior-author papers:
- Bull Math Biol, 2026 (senior author): Chemotactic Feedback Controls Patterning in Hybrid Tumor-Stroma Model. PubMed 42671714
- Biomedicines, 2026 (senior author): FTU-Seek: Foundation Model-Guided Hard-Negative Learning for Sparse Functional Tissue Unit Segmentation. PubMed 42792676
- Crit Rev Oncol Hematol, 2026 (senior author): Human endogenous retroviruses in liver cancer: A double-edged sword in tumor progression and anti-tumor immunity. PubMed 41974391
- iScience, 2026 (senior author): HERV2365 upregulates FGF1 expression by sponging miR-326 to promote the progression of intrahepatic cholangiocarcinoma. PubMed 42164859
- BMC Cancer, 2026 (senior author): FGFR4-high expression is associated with an immune-responsive phenotype in HCC and predicts inferior efficacy of lenvatinib plus PD-1 blockade. PubMed 42104313
- Mol Cell Endocrinol, 2026 (senior author): FNDC4 regulates M2 polarization of tumor-associated macrophages to affect colorectal cancer metastasis. PubMed 41616831
- Sci Rep, 2026 (senior author): Cancer-Associated fibroblasts regulate the development of cholangiocarcinoma through IL-6/STAT3/AKR1C3 signaling axis. PubMed 41735359
- Front Oncol, 2025 (senior author): Comprehensive identification of microbial and metabolomic factors impacting ICC recurrence. PubMed 41767584
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion